NTT Electronics starts shipping 140 Gbaud High-performance Coherent DSP
6.3.2023 21:00:00 EET | Business Wire | Press release
NTT Electronics, a leading supplier of coherent Digital Signal Processor (DSP) solutions to system and module manufacturers worldwide, today announced start of 140 Gbaud high-performance coherent DSP (ExaSPEED GAIA) shipment to customers. ExaSPEED GAIA achieves world's largest transmission capacity of 1.2 Tbit/s per wavelength by utilizing a programmable baud rate of up to 140 Gbaud powered by a flexible coded modulation scheme and advanced 5nm FinFET CMOS process.
“We are excited to add the ExaSPEED GAIA DSP to our product portfolio which cuts the power consumption per bit to half while doubling the baud rate over earlier product offering,” said Satoshi Shigematsu, NTT Electronics General Manager of Broadband System & Device Business Unit. “We believe this high-performance DSP will help our customers offer highly differentiated optical transmission equipment and systems”, he added.
The programmable baud rate can support very fine granularity that enables ExaSPEED GAIA to adapt to a range of links while maximizing spectral efficiency. These include short-reach data center interconnects (DCI), terrestrial metro links with cascaded ROADMs, and ultra-long-haul sub-sea links. Customers can use a wide range of 400G interfaces in 1.2T (3x400GbE) for DCI, 800G (2x400GbE) for metro and 400G (1x400GbE) for sub-sea applications. This capability helps simplify interfaces and optimize Capital/Operational expenditure. Moreover, ExaSPEED GAIA also offers fine capacity tuning in 50G increments to respond to various customer requirements.
Flexible coded modulation is the newly-developed coding scheme to efficiently implement advanced constellation shaping, forward error correction (FEC), and high-order modulation format with high performance and low power. This enables ExaSPEED GAIA to support thousands of operational modes that cover a multitude of customer's transmission links with high energy efficiency. To enhance the performance, ExaSPEED GAIA employs a number of novel compensation algorithms including nonlinear distortion compensation, adaptive fast state of polarization (SOP) tracking, fast device and transmission characteristics estimation, and ultra-long CD compensation for high-baud rate systems*. The performance of ExaSPEED GAIA can be further optimized by combining it with NTT Electronics’ industry-leading high speed coherent driver module (UHB-CDM).
"We are very impressed with the performance of NTT Electronics’ latest ExaSPEED GAIA DSP," commented Hideki Matsui, Vice Head of Photonics System Business Unit, Fujitsu Limited. “This revolutionary DSP makes our products more competitive in the market and enables us to offer innovative solutions. It opens up a new 'terabit era,' which will be a game changer in our industry,” he added.
“This state-of-the-art DSP, we believe would be key to realize the future information-centric society,” said Akio Goto, General Manager of Photonics Device Development Division, NEC Corporation. He also said, “We are excited to introduce ExaSPEED GAIA in conjunction with CDM in our DWDM products to build diverse, high-throughput and green optical networks.”
* https://group.ntt/en/newsrelease/2022/09/05/220905a.html
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230306005007/en/
Contact information
NTT Electronics Contact :
Atul Srivastava, CEO & CTO
NTT Electronics America, Inc.
Tel : +1-201-556-1770
Email : pr@nel-america.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom